Aipalolitovorelizumab (QL1706)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Aipalolitovorelizumab (QL1706), covering 2026-01-08 to 2026-01-08. Get the full timeline:
Most recent: Clinical Trial Update: A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation [Phase 2]